Table 3 Breakdown and description of the toxicities of IT nivolumab by IT nivolumab dose level as well as for the individual patient. After the first cycle (IT nivolumab alone), assignment of toxicity to either IT, IV or IT/IV nivolumab was inherently more difficult, as IV and IT nivolumab were administered within 24 h of each other
IT nivolumab dose | Patient Accession Number | Adverse event | Cycle number | Grade 1 | Grade 2 |
|---|---|---|---|---|---|
5 mg | 1 | Paresthesia | 11 | 1 | |
Aphasia | 19 | 1 | |||
20 mg | 8 | Neck pain | 1 | 1 | |
10 | Nausea | 1 | 1 | ||
19 | Nausea | 1 | 1 | ||
20a | Dizziness | 1 | 1 | ||
Nausea | 1 | 1 | |||
50 mg | 24 | Pruritus | 1 | 1 | |
Nausea | 1 | 1 | |||
25a | Dizziness | 1 | 1 | ||
Paresthesia | 1 | 1 | |||
Vomiting | 1 | 1 | |||
Nausea | 16 | 1 | |||
26 | Anorexia | 1 | 1 | ||
Dizziness | 1 | 1 | |||
Nausea | 1 | 1 | |||
Vomiting | 1 | 1 | |||
27a | Nausea | 1 | 1 | ||
Dizziness | 1 | 1 | |||
Vomiting | 1 | 1 | |||
30aa | Visual changes | 1 | 1 |
